Impact of diabetes mellitus on prediction of clinical outcome after coronary revascularization by 18F-FDG SPECT in patients with ischemic left ventricular dysfunction

Journal of Nuclear Medicine

Volumn 47, Issue 1, 2006, Pages 69-73

  Schinkel, Arend F L ^a   Poldermans, Don ^a   Rizzello, Vittoria ^a   Van Domburg, Ron T ^a   Valkema, Roelf ^a   Elhendy, Abdou ^a   Biagini, Elena ^a   Krenning, Eric P ^a   Simoons, Maarten L ^a   Bax, Jeroen J ^b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

18F FDG SPECT; Diabetes mellitus; Myocardial viability

Indexed keywords

FLUORODEOXYGLUCOSE F 18; TETROFOSMIN TC 99M; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; ECHOCARDIOGRAPHY; FEMALE; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE ISCHEMIA; HEART MUSCLE REVASCULARIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CORONARY ARTERY BYPASS GRAFT; HEART LEFT VENTRICLE FUNCTION; METHODOLOGY; MIDDLE AGED; NETHERLANDS; OUTCOME ASSESSMENT; PROGNOSIS; RISK ASSESSMENT; RISK FACTOR; SCINTISCANNING; STATISTICS; TREATMENT OUTCOME;

COMORBIDITY; CORONARY ARTERY BYPASS; DIABETES MELLITUS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; NETHERLANDS; OUTCOME ASSESSMENT (HEALTH CARE); PROGNOSIS; RADIOPHARMACEUTICALS; RISK ASSESSMENT; RISK FACTORS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TREATMENT OUTCOME; VENTRICULAR DYSFUNCTION, LEFT;

EID: 34248652117     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Dries DL, Sweitzer NK, Drazner MH, et al. Prognostic impact of diabetes mellitus in patients with heart failure according to the etiology of left ventricular systolic dysfunction. J Am Coll Cardiol. 2001;38:421-428.
2. Shindler DM, Kostis JB, Yusuf S, et al. Diabetes mellitus, a predictor of morbidity and mortality in the Studies of Left Ventricular Dysfunction (SOLVD) Trials and Registry. Am J Cardiol. 1996;77:1017-1020.
3. Das SR, Drazner MH, Yancy CW, et al. Effects of diabetes mellitus and ischemic heart disease on the progression from asymptomatic left ventricular dysfunction to symptomatic heart failure: a retrospective analysis from the Studies of Left Ventricular Dysfunction (SOLVD) Prevention Trial. Am Heart J. 2004;148:883-888.
4. Tillisch J, Brunken R, Marshall R, et al. Reversibility of cardiac wall motion abnormalities predicted by positron tomography. N Engl J Med. 1986;314:884-888.
5. Eitzman D, Al-Aouar Z, Kanter H, et al. Clinical outcome of patients with advanced coronary artery disease after viability studies with positron emission tomography. J Am Coll Cardiol. 1992;20:559-565.
6. Schoder H, Campisi R, Ohtake T, et al. Blood flow-metabolism imaging with positron emission tomography in patients with diabetes mellitus for the assessment of reversible left ventricular contractile dysfunction. J Am Coll Cardiol. 1999;33:1328-1337.
7. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care. 2003;26(suppl 1):S5-S20.
8. Bourdillon PD, Broderik TM, Sawada SG, et al. Regional wall motion index for infarct and non-infarct region after reperfusion in acute myocardial infarction: comparison with global wall motion index. J Am Soc Echocardiogr. 1989;2:398-407.
9. 18F-FDG SPECT using acipimox for the assessment of myocardial viability. J Nucl Med. 2003;44:877-883.
10. Musatti L, Maggi E, Moro E, et al. Bioavailability and pharmacokinetics in man of acipimox, a new antilipolytic and hypolipemic agent. J Int Med Res. 1981;9:381-386.
11. Knuuti MJ, Ykii-Jarvinen H, Voipio-Pulkki LM, et al. Enhancement of myocardial [fluorine-18]fluorodeoxyglucose uptake by a nicotinic acid derivative. J Nucl Med. 1994;35:989-998.
12. Nuutila P, Knuuti MJ, Raitakari M, et al. Effect of antilipolysis on heart and skeletal muscle glucose uptake in overnight fasted humans. Am J Physiol. 1994;267:E941-E946.
13. van Lingen A, Huijgens PC, Visser FC, et al. Performance characteristics of a 511-keV collimator for imaging positron emitters with a standard gamma-camera. Eur J Nucl Med. 1992;19:315-321.
14. Wijns W, Vatner SF, Camici PG. Hibernating myocardium. N Engl J Med. 1998;339:173-181.
15. Schinkel AF, Bax JJ, Poldermans D. Clinical assessment of myocardial hibernation. Heart. 2005;91:111-117.
16. McCullough PA, Philbin EF, Spertus JA, et al. Confirmation of a heart failure epidemic: findings from the Resource Utilization Among Congestive Heart Failure (REACH) Study. J Am Coll Cardiol. 2002;39:60-69.
17. Burke JP, Williams K, Gaskill SP, et al. Rapid rise in the incidence of type 2 diabetes from 1987 to 1996: results from the San Antonio Heart Study. Arch Intern Med. 1999;159:1450-1456.
18. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care. 1998;21:1414-1431.
19. Abbott RD, Donahue RP, Kannel WB, et al. The impact of diabetes on survival following myocardial infarction in men vs women: the Framingham Study. JAMA. 1988;260:3456-3460.
20. Bax JJ, Poldermans D, Elhendy A, et al. Sensitivity, specificity, and predictive accuracies of various noninvasive techniques for detecting hibernating myocardium. Curr Probl Cardiol. 2001;26:141-186.
21. Bax JJ, Cornel JH, Visser FC, et al. Prediction of improvement of contractile function in patients with ischemic ventricular dysfunction after revascularization by fluorine-18 fluorodeoxyglucose single-photon emission computed tomography. J Am Coll Cardiol. 1997;30:377-383.
22. Bax JJ, Visser FC, Poldermans D, et al. Relationship between preoperative viability and postoperative improvement in LVEF and heart failure symptoms. J Nucl Med. 2001;42:79-86.
23. Martin WH, Delbeke D, Patton JA, et al. FDG-SPECT: correlation with FDG-PET. J Nucl Med. 1995;36:988-995.
24. Chen EQ, MacIntyre WJ, Go RT, et al. Myocardial viability studies using fluorine-18-FDG SPECT: a comparison with fluorine-18-FDG PET. J Nucl Med. 1997;38:582-586.
25. 18F] Fluorodeoxyglucose single photon emission computed tomography: can it replace PET and thallium SPECT for the assessment of myocardial viability? Circulation. 1998;97:843-850.
26. Bax JJ, Veening MA, Visser FC, et al. Optimal metabolic conditions during fluorine-18 fluorodeoxyglucose imaging: a comparative study using different protocols. Eur J Nucl Med. 1997;24:35-41.
27. Bax JJ, Visser FC, Poldermans D, et al. Feasibility, safety and image quality of cardiac FDG studies during hyperinsulinaemic-euglycaemic clamping. Eur J Nucl Med. 2002;29:452-457.
28. Flotats A, Carrio I, Estorch M, et al. Nitrate administration to enhance the detection of myocardial viability by technetium-99m tetrofosmin single-photon emission tomography. Eur J Nucl Med. 1997;24:767-773.